<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04175704</url>
  </required_header>
  <id_info>
    <org_study_id>UBP-A115-IgE</org_study_id>
    <nct_id>NCT04175704</nct_id>
  </id_info>
  <brief_title>Evaluating the Safety and Tolerability and Determining the PK and PD of Single Dose UB-221 in Chronic Spontaneous Urticaria</brief_title>
  <official_title>A Phase I, Randomized, Single-Blind, Placebo-Controlled, Single Ascending Dose Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of UB-221 as an Add-on Therapy in Patients With Chronic Spontaneous Urticaria</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>United BioPharma</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>United BioPharma</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study is to evaluate the profiles of safety, tolerability, pharmacokinetics, and
      pharmacodynamics of UB-221. In this study, safety profile of UB-221 and maximum tolerated
      dose (MTD) is to be investigated using sentinel dosing strategy. The starting dose of 0.2
      mg/kg is selected based on the evaluation and comparison of various approaches including
      NOAEL, MABEL (minimum anticipated biological effect level), and experiences from other
      anti-IgE mAb drugs in development.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a phase I, randomized, single-blind, placebo-controlled, parallel group, single
      ascending dose study to evaluate the safety, tolerability, pharmacokinetics (PK), and
      pharmacodynamics (PD) of a single dose of UB-221 as an add-on therapy in chronic spontaneous
      urticaria (CSU) subjects who fail to respond to the first line H1-antihistamine treatment.
      Only the qualified subjects will be blinded to receive treatment. Each subject will receive
      only one dose of UB-221 or placebo.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">May 30, 2020</start_date>
  <completion_date type="Anticipated">January 30, 2023</completion_date>
  <primary_completion_date type="Anticipated">November 30, 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To evaluate the safety (Adverse event (AE)/ serious adverse event (SAE)) of UB-221 in CSU patients</measure>
    <time_frame>99 days</time_frame>
    <description>1.Adverse event (AE)/ serious adverse event (SAE) reporting: from treatment to EOS</description>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">32</enrollment>
  <condition>Chronic Idiopathic Urticaria</condition>
  <arm_group>
    <arm_group_label>Cohort 1</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>0.2 mg/kg UB-221 or placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort2</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>0.6 mg/kg UB-221 or placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 3</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>2 mg/kg UB-221 or placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 4</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>6 mg/kg UB-221 or placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>UB-221</intervention_name>
    <description>Name: UB-221 Active ingredient: Anti-IgE monoclonal antibody Dosage form: UB-221 drug product is presented as a sterile liquid for intravenous (IV) infusion. Each vial contains 75 mg/mL UB-221 in 1.12 mL of buffered solution</description>
    <arm_group_label>Cohort 1</arm_group_label>
    <arm_group_label>Cohort 3</arm_group_label>
    <arm_group_label>Cohort 4</arm_group_label>
    <arm_group_label>Cohort2</arm_group_label>
    <other_name>recombinant anti-IgE humanized IgG1 monoclonal antibody</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subjects aged â‰¥ 18 years

          -  Subjects who are able and willing to provide the informed consent

          -  Subjects diagnosed with chronic spontaneous urticaria (CSU) for more than six weeks
             prior to the screening visit as confirmed by investigators based on medical history.

        Exclusion Criteria:

          -  History of significant diseases (other than CSU) or major clinical conditions by the
             investigator's judgment, such as auto-immune disease or psychiatric and behavioral
             conditions from which the investigator considers the subject not suitable to
             participate in this study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Mico Hsu, Master</last_name>
    <phone>+886-3-668-4800</phone>
    <phone_ext>3201</phone_ext>
    <email>mico.hsu@unitedbiopharma.com</email>
  </overall_contact>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>November 12, 2019</study_first_submitted>
  <study_first_submitted_qc>November 21, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">November 25, 2019</study_first_posted>
  <last_update_submitted>March 23, 2020</last_update_submitted>
  <last_update_submitted_qc>March 23, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 25, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Urticaria</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Antibodies, Monoclonal</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

